Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients
© Szerző(k)/The Author(s).
In critically ill COVID-19 patients, the failure of the cardiorespiratory system can be due to one of the following: (1) cytokine storm, haemophagocytosis – septic shock, (2) unmanageable hypoxemia, (3) isolated organ failure or as part of multi-organ failure. Herein we give an overview of the therapeutic options for treating or preventing these disease states. In recent years, CytoSorb-haemoperfusion to remove cytokines has shown promising results in the treatment of septic shock. Inhalational nitric oxide (iNO), inhalational epoprostenol and veno-venous extracorporeal membrane oxygenation (ECMO) are options in severe hypoxemia that is unresponsive to conventional mechanical ventilation. Renal failure is a frequent component of the multi-organ failure usually seen with disease progression and necessitates starting one of the available continuous renal replacement modalities. Orv Hetil. 2020; 161(17): 704–709.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 161(2020), 17 vom: 01. Apr., Seite 704-709 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Emelt szintű szervtámogató és életfenntartó kezelések kritikus állapotú COVID–19-fertőzött betegeken |
|---|
| Beteiligte Personen: |
Berhés, Mariann [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31C4KY9ESH |
|---|
| Anmerkungen: |
Date Completed 27.04.2020 Date Revised 18.12.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2020.31813 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309087341 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309087341 | ||
| 003 | DE-627 | ||
| 005 | 20231225133136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2020.31813 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309087341 | ||
| 035 | |a (NLM)32324366 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Berhés, Mariann |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients |
| 246 | 3 | 3 | |a Emelt szintű szervtámogató és életfenntartó kezelések kritikus állapotú COVID–19-fertőzött betegeken |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Szerző(k)/The Author(s) | ||
| 520 | |a In critically ill COVID-19 patients, the failure of the cardiorespiratory system can be due to one of the following: (1) cytokine storm, haemophagocytosis – septic shock, (2) unmanageable hypoxemia, (3) isolated organ failure or as part of multi-organ failure. Herein we give an overview of the therapeutic options for treating or preventing these disease states. In recent years, CytoSorb-haemoperfusion to remove cytokines has shown promising results in the treatment of septic shock. Inhalational nitric oxide (iNO), inhalational epoprostenol and veno-venous extracorporeal membrane oxygenation (ECMO) are options in severe hypoxemia that is unresponsive to conventional mechanical ventilation. Renal failure is a frequent component of the multi-organ failure usually seen with disease progression and necessitates starting one of the available continuous renal replacement modalities. Orv Hetil. 2020; 161(17): 704–709 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a CytoSorb | |
| 650 | 4 | |a ECMO | |
| 650 | 4 | |a inhalational nitric oxide | |
| 650 | 4 | |a inhalált nitrogén-oxid | |
| 650 | 4 | |a intensive therapy | |
| 650 | 4 | |a intenzív kezelés | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Nitric Oxide |2 NLM | |
| 650 | 7 | |a 31C4KY9ESH |2 NLM | |
| 700 | 1 | |a Fábián, Ákos |e verfasserin |4 aut | |
| 700 | 1 | |a László, István |e verfasserin |4 aut | |
| 700 | 1 | |a Végh, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Molnár, Csilla |e verfasserin |4 aut | |
| 700 | 1 | |a Fülesdi, Béla |e verfasserin |4 aut | |
| 700 | 1 | |a Koszta, György |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 161(2020), 17 vom: 01. Apr., Seite 704-709 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:2020 |g number:17 |g day:01 |g month:04 |g pages:704-709 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2020.31813 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 2020 |e 17 |b 01 |c 04 |h 704-709 | ||